Related Experiment Videos
Pneumonitis induced by rifampicin
N Kunichika1, N Miyahara, K Kotani
1Department of Internal Medicine, National Sanyo Hospital, Yamaguchi, Japan. nao_k@d2.dion.ne.jp
Thorax
|October 31, 2002
Summary
Rifampicin-induced pneumonitis, a rare adverse reaction during tuberculosis treatment, may stem from complex immune responses involving lymphocytes. Early recognition and corticosteroid treatment are key for patient recovery.
Area of Science:
- Pulmonology
- Infectious Diseases
- Immunology
Background:
- Tuberculosis (TB) treatment commonly involves a multi-drug regimen including rifampicin (RFP), isoniazid (INH), and ethambutol (EB).
- Drug-induced pneumonitis is a potential, though uncommon, adverse effect of anti-TB medications.
Observation:
- An 81-year-old male developed fever and dyspnea on day 9 of anti-TB therapy.
- Chest radiography revealed new pulmonary infiltrates, and bronchoalveolar lavage showed increased lymphocytes.
Findings:
- The patient's symptoms and radiographic findings improved after discontinuing anti-TB drugs and administering methylprednisolone.
- A positive lymphocyte stimulation test for RFP and T-cell subset analysis in BAL fluid suggest RFP-induced pneumonitis.
- Reintroduction of INH and EB did not cause symptom recurrence.
Implications:
- Rifampicin-induced pneumonitis is likely an immune-mediated hypersensitivity reaction.
- Prompt diagnosis and management with corticosteroids are crucial for resolving RFP-induced pneumonitis.
- This case highlights the importance of considering drug-induced lung injury in patients on anti-TB treatment presenting with new respiratory symptoms.